Key Highlights
- Redwire partners with Wake Forest Institute of Regenerative Medicine (WFIRM) to launch a bioprinting experiment on the ISS.
- Experiment to analyze microgravity’s impact on bioprinting vascularized liver tissue constructs.
- Focus on improving space bioprinting techniques with the goal of bioprinting full-scale organs.
- Launch includes four drug manufacturing experiments in the PIL-BOX system.
- Experiment supported by the ISS National Laboratory and NASA as part of the Vascular Tissue Challenge.
Source: Business Wire
Notable Quote
- “Redwire is building tremendous momentum with our space biotech capabilities as we engage with new customers and partners to identify critical targets for breakthrough research and increase throughput of bioprinting and drug manufacturing experiments using our space-based suite of hardware. We are grateful for our strong partnership with Wake Forest Institute of Regenerative Medicine along with crucial support from the ISS National Lab and NASA. We’re eager to build on our recent trailblazing results and further validate our microgravity research and manufacturing capabilities that could one day translate to life-saving medical products and drugs.” — John Vellinger, President of In-Space Industries at Redwire
SoHC's Take
Redwire Corporation’s latest mission to the ISS marks a significant milestone in space-based biotechnology research. By focusing on bioprinting vascularized liver tissue constructs in microgravity, Redwire is addressing critical challenges in regenerative medicine and organ shortages on Earth. The collaboration with WFIRM and the support from ISS National Laboratory and NASA underscore the importance of this research. Furthermore, the continuation of drug manufacturing experiments with the PIL-BOX system highlights Redwire’s commitment to optimizing space-based biotechnological processes. This experiment not only reinforces Redwire’s leading position in space infrastructure but also paves the way for groundbreaking advancements in medical science.
